ライフサイエンスコーパス: posaconazole

1 e analysis: 19 received ABLC and 21 received posaconazole.

2 ofungin, 98.2% for micafungin, and 98.1% for posaconazole.

3 ates of Candida albicans were tested against posaconazole.

4 en the Vitek 2 and BMD methods was 95.6% for posaconazole.

5 micafungin and after 48 h of incubation for posaconazole.

6 = 1 microg/ml was used for amphotericin and posaconazole.

7 s, including voriconazole, itraconazole, and posaconazole.

8 photoactivatable cross-linking derivative of posaconazole.

9 of < or = 0.25 microg/ml was established for posaconazole.

10 in three patients and in one, termination of posaconazole.

11 redict the susceptibility of Candida spp. to posaconazole.

12 71 clinical isolates of Candida spp. against posaconazole.

13 g the susceptibility of filamentous fungi to posaconazole.

14 r susceptibility testing of the new triazole posaconazole.

15 er benznidazole monotherapy or combined with posaconazole.

16 traconazole, voriconazole, ravuconazole, and posaconazole.

17 r reduced susceptibility to itraconazole and posaconazole.

18 han three dilutions) was also low (<2%) with posaconazole.

19 midine, and two antifungals ravuconazole and posaconazole.

20 ilar to that reported for amphotericin B and posaconazole.

21 e who were changed to either itraconazole or posaconazole.

22 whereas all three were inhibited by 1 mug/ml posaconazole.

23 pectively), itraconazole (0.5 and 1 mug/ml), posaconazole (0.5 and 1 mug/ml), isavuconazole (4 and 4

24 er than the ECVs ranged from 1.1 to 5.7% for posaconazole, 0.0 to 1.6% for voriconazole, and 0.7 to 4

25 rog/ml; itraconazole, 0.06 to 0.5 microg/ml; posaconazole, 0.03 to 0.25 microg/ml; voriconazole, 0.01

26 /4 (94.8%); voriconazole, 0.03/0.12 (98.6%); posaconazole, 0.12/0.5 (95.9%); amphotericin, 0.5/2 (88.

27 (97.7%); A. flavus, itraconazole, 1 (99.6%); posaconazole, 0.25 (95%); voriconazole, 1 (98.1%); A. ni

28 2 (99.3%); A. niger, itraconazole, 2 (100%); posaconazole, 0.5 (96.9%); voriconazole, 2 (99.4%); A. t

29 ses): A. fumigatus, itraconazole, 1 (98.8%); posaconazole, 0.5 (99.2%); voriconazole, 1 (97.7%); A. f

30 (99.4%); A. terreus, itraconazole, 1 (100%); posaconazole, 0.5 (99.7%); voriconazole, 1 (99.1%); A. v

31 (98.1%); A. nidulans, itraconazole, 1 (95%); posaconazole, 1 (97.7%); voriconazole, 2 (99.3%); A. nig

32 .1%); A. versicolor, itraconazole, 2 (100%); posaconazole, 1 (not applicable); voriconazole, 2 (97.5%

33 te experiment, guinea pigs were treated with posaconazole (10 mg/kg of body weight orally [p.o.] twic

34 and 89.3%); all were superior to placebo or posaconazole (10% and 16.7%, p < 0.0001).

35 otherapy (both 96%) versus placebo (17%) and posaconazole (16%, p < 0.0001).

36 en/probable mold infections were considered (posaconazole, 2.7% vs itraconazole, 10.7%, P= .02).

37 B (18 to 25 mm), itraconazole (11 to 21 mm), posaconazole (28 to 35 mm), and voriconazole (25 to 33 m

38 B (18 to 27 mm), itraconazole (18 to 26 mm), posaconazole (28 to 38 mm), and voriconazole (29 to 39 m

39 5 to 24 mm), itraconazole (20 to 31 mm), and posaconazole (33 to 43 mm); A. fumigatus ATCC MYA-3626,

40 placebo b.i.d.; benznidazole 200 mg b.i.d. + posaconazole 400 mg b.i.d.; or placebo 10 mg b.i.d. T. c

41 a and Spain who were randomized to 4 groups: posaconazole 400 mg twice a day (b.i.d.); benznidazole 2

42 er), and 48 h (other species); and (iii) the posaconazole 5-microg disk, voriconazole 1-microg disk,

43 pofungin 5-microg disks [BBL and Oxoid], and posaconazole 5-microg disks).

44 The object of this study was to test whether posaconazole, a broad-spectrum antifungal agent inhibiti

45 ant to the ergosterol biosynthesis inhibitor posaconazole, a drug proposed for use against T. cruzi i

46 r study, we evaluated efficacy and safety of posaconazole, a new extended-spectrum triazole, as salva

47 Posaconazole absorption was assessed on day 14.

48 Posaconazole accumulates at high concentrations in dHL-6

49 to validate a potential surrogate marker for posaconazole activity against indicated species.

50 the 90% effective concentration threshold of posaconazole activity against R. oryzae could be achieve

51 adjacent bone was treated successfully with posaconazole after therapy with itraconazole and amphote

52 roth microdilution susceptibility testing of posaconazole against 146 clinical isolates of filamentou

53 le against 55 (60%) of the 91 isolates, with posaconazole against 46 (51%) of the 91 isolates, and wi

54 tion, E-test, and disk diffusion methods for posaconazole against Candida spp.

55 al and clinical studies indicate activity of posaconazole against Fusarium.

56 thway, would enhance the in vivo activity of posaconazole against Rhizopus oryzae, the Mucorales spec

57 For MIC-0 of posaconazole, agreement levels were 86% for the 6-h XTT

58 g the susceptibility of filamentous fungi to posaconazole; agreement (+/-2 log2 dilutions) between th

59 rpose of this study was to determine whether posaconazole alone or combined with benznidazole were su

60 in the fly model of mucormycosis (65% vs 57% posaconazole alone) and with significant reductions in c

61 e for emergence of reduced susceptibility to posaconazole among Candida spp.

62 to fluconazole, voriconazole, itraconazole, posaconazole, amphotericin B, and caspofungin for 383 in

63 tly enhanced the activity of the antifungals posaconazole, amphotericin B, and caspofungin, likely th

64 tro activities of fluconazole, voriconazole, posaconazole, amphotericin B, anidulafungin, caspofungin

65 reover, they both acted synergistically with posaconazole, an azole currently used in the treatment o

66 Only 13.3% of those receiving posaconazole and 10% receiving placebo achieved the prim

67 percentage of breakthrough IFDs (18.9% with posaconazole and 38.7% with itraconazole, P< .001).

68 ysis, 90% of the patients receiving low-dose posaconazole and 80% of those receiving high-dose posaco

69 ysis, 92% of the patients receiving low-dose posaconazole and 81% receiving high-dose posaconazole, a

70 , compared with 80% receiving benznidazole + posaconazole and 86.7% receiving benznidazole monotherap

71 ution and agar diffusion methods for testing posaconazole and amphotericin B in the clinical laborato

72 substantially less expensive to produce than posaconazole and are appropriate for further development

73 After failing posaconazole and being intolerant to amphotericin, he wa

74 was not observed at 360 days; benznidazole + posaconazole and benznidazole monotherapy (both 96%) ver

75 cutaneous H. aspergillata infection while on posaconazole and caspofungin therapy.

76 verall agreement was lower between reference posaconazole and Etest MICs (94 to 97%) and by both meth

77 fficacy of antifungal prophylaxis (AFP) with posaconazole and itraconazole in a real-life setting of

78 By comparison, posaconazole and itraconazole resolved GM antigenemia, r

79 conazole and voriconazole and 90 to 91% with posaconazole and itraconazole when EUCAST MICs were comp

80 When comparing the groups taking posaconazole and itraconazole, there were no significant

81 fective against Chagas, and antifungal drugs posaconazole and ravuconazole have entered clinical tria

82 Combinations of posaconazole and tacrolimus were synergistic in checkerb

83 growth inhibition and fungicidal activity of posaconazole and tacrolimus, alone and in combination, a

84 The specific subcellular location of posaconazole and the mechanism by which cell-associated

85 The MIC results obtained for both posaconazole and voriconazole after only 24 h of incubat

86 performed 24- and 48-h MIC determinations of posaconazole and voriconazole against more than 16,000 c

87 ng 13 species rarely isolated from blood, to posaconazole and voriconazole as well as four licensed s

88 which itraconazole MICs were >2 mug/ml, the posaconazole and voriconazole MICs were greater than the

89 onazole MICs were < or = 2 microg/ml against posaconazole and voriconazole using the CLSI BMD method.

90 Posaconazole and voriconazole were active (MIC, < or = 1

91 had MICs equal to or less than the ECV]) for posaconazole and voriconazole, respectively, were as fol

92 The modal MICs (mug/ml) for posaconazole and voriconazole, respectively, were as fol

93 We tested 16,191 strains of Candida against posaconazole and voriconazole, using the CLSI M27-A3 bro

94 the 24- and 48-h results was 99.6% for both posaconazole and voriconazole.

95 ecies-specific clinical breakpoints for both posaconazole and voriconazole.

96 Aspergillus spp. were comparable to those of posaconazole and voriconazole; the MIC90 values for isav

97 uconazole was the weakest inhibitor, whereas posaconazole and VT-1161 were the strongest CYP51 inhibi

98 ructures of C. albicans CYP51 complexes with posaconazole and VT-1161, providing a molecular mechanis

99 in a three-dilution range) between reference posaconazole and YeastOne MICs was 98 to 100% at 16 to 2

100 oriconazole, ketoconazole, itraconazole, and posaconazole) and topically (miconazole and clotrimazole

101 2 dilutions and 99.6% (itraconazole), 87.7% (posaconazole), and 96.3% (voriconazole) at +/-1 dilution

102 s was excellent: 100% (itraconazole), 98.4% (posaconazole), and 99.6% (voriconazole) assessing EA at

103 Voriconazole, posaconazole, and ravuconazole all were very active (99%

104 n B, flucytosine, fluconazole, voriconazole, posaconazole, and ravuconazole were determined by the Na

105 conazole, three new triazoles (voriconazole, posaconazole, and ravuconazole), and amphotericin B.

106 dida spp. against fluconazole, voriconazole, posaconazole, and ravuconazole.

107 ndida spp to the new triazoles voriconazole, posaconazole, and ravuconazole.

108 onazole; the MIC90 values for isavuconazole, posaconazole, and voriconazole against Candida spp. were

109 eptibility testing methods for itraconazole, posaconazole, and voriconazole by testing 245 Aspergillu

110 o compare MICs of fluconazole, itraconazole, posaconazole, and voriconazole obtained by the European

111 with CLSI BMD method M27-A3 for fluconazole, posaconazole, and voriconazole susceptibility testing of

112 Testing of susceptibility to amphotericin B, posaconazole, and voriconazole was subsequently performe

113 developed ECVs for triazoles (itraconazole, posaconazole, and voriconazole) and common Aspergillus s

114 ngin, micafungin, fluconazole, itraconazole, posaconazole, and voriconazole) using CLSI methods.

115 the EUCAST and CLSI results for fluconazole, posaconazole, and voriconazole, respectively, for each s

116 ECVs (expressed as mug/ml) for fluconazole, posaconazole, and voriconazole, respectively, were as fo

117 entages of non-WT isolates for itraconazole, posaconazole, and voriconazole, respectively, were as fo

118 for five Aspergillus spp. and itraconazole, posaconazole, and voriconazole.

119 o amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole.

120 ketoconazole, itraconazole, voriconazole, or posaconazole; and dronedarone.

121 apsilosis) were susceptible to voriconazole, posaconazole, anidulafungin, caspofungin, and micafungin

122 14alpha-demethylase (CYP51), complexed with posaconazole, another antifungal agent fluconazole and a

123 ompounds have a simple structure compared to posaconazole, another L14DM inhibitor that is an anti-Ch

124 Here we show that posaconazole, another triazole, also blocks cholesterol

125 n the basis of compassionate treatment data, posaconazole appears to be effective for treatment of zy

126 One patient in the ABLC arm and none in posaconazole arm developed IFI (5% vs. 0%, P=0.48).

127 cal Evaluation Trial, and bring attention to posaconazole as a potential complementary anti-breast ca

128 l trial to assess the efficacy and safety of posaconazole as compared with the efficacy and safety of

129 ose posaconazole and 81% receiving high-dose posaconazole, as compared with 38% receiving benznidazol

130 onazole and 80% of those receiving high-dose posaconazole, as compared with 6% receiving benznidazole

131 present work we cocrystallized the P450 with posaconazole at 2.5 A resolution.

132 400 mg twice daily (high-dose posaconazole), posaconazole at a dose of 100 mg twice daily (low-dose p

133 We randomly assigned patients to receive posaconazole at a dose of 400 mg twice daily (high-dose

134 We compared the crystal structure of posaconazole-bound CYP46A1 with those of the P450 in com

135 ours and could be competitively inhibited by posaconazole but not voriconazole.

136 ions (MECs) of amphotericin B, voriconazole, posaconazole, caspofungin, and micafungin were assessed

137 (amphotericin B, fluconazole, voriconazole, posaconazole, caspofungin, anidulafungin, and micafungin

138 Posaconazole monotherapy or posaconazole combined with benznidazole achieved high RT

139 Posaconazole concentrates within host cell membranes and

140 The antifungal posaconazole concentrates within host cells and protects

141 HL-60] cells) and then exposed to a range of posaconazole concentrations.

142 oaded ex vivo with the lipophilic antifungal posaconazole could improve delivery of antifungals to th

143 ketoconazole, itraconazole, voriconazole, or posaconazole; cyclosporine; erythromycin or clarithromyc

144 Posaconazole demonstrated trypanostatic activity during

145 order to propose quality control limits for posaconazole disk diffusion susceptibility tests on Muel

146 three lots of prepared media using 5-microg posaconazole disks in each of eight laboratories to gene

147 For A. fumigatus, posaconazole E-test MICs had better concordance with ref

148 rast, with amphotericin B, itraconazole, and posaconazole, E-test results were more dependent on the

149 B (EA, 100%), voriconazole (EA, 93.7%), and posaconazole (EA, 94.8%) against C. albicans, but its er

150 Posaconazole EUCAST MICs were also substantially lower t

151 Our studies reported here demonstrate that posaconazole exhibits in vitro synergy with caspofungin

152 teractions determine the submicromolar Kd of posaconazole for CYP46A1.

153 RD9 deficiency and the potential efficacy of posaconazole for this indication.

154 Contact-dependent transfer of posaconazole from dHL-60 cells to hyphae was observed in

155 ay 14, except for 2 patients in the low-dose posaconazole group who tested positive on day 60.

156 arison of the benznidazole group with either posaconazole group).

157 arison of the benznidazole group with either posaconazole group); in the per-protocol analysis, 90% o

158 However, significantly more patients in the posaconazole groups than in the benznidazole group had t

159 ecause of severe cutaneous reactions; in the posaconazole groups, 4 patients had aminotransferase lev

160 e same isolates had MICs to voriconazole and posaconazole > or = 2 microg/ml.

161 Posaconazole has been approved for prophylaxis in HSCT.

162 Posaconazole has shown trypanocidal activity in murine m

163 of combination therapy with benznidazole and posaconazole have not been tested in Trypanosoma cruzi c

164 otericin; newer triazoles (ie, voriconazole, posaconazole) have been demonstrated to be useful in ref

165 The new triazole agents, voriconazole and posaconazole, have a broad spectrum of antifungal activi

166 riconazole are in the same triazole class as posaconazole, have CLSI-approved interpretive MIC breakp

167 The availability of posaconazole in an oral formulation that can be administ

168 We also analyzed the accommodation of posaconazole in the active site of the target enzymes, C

169 fluconazole, itraconazole, voriconazole, and posaconazole in vitro.

170 e and the mechanism by which cell-associated posaconazole inhibits fungal growth remain uncharacteriz

171 Posaconazole is widely used for prophylaxis against inva

172 A. nidulans, and A. terreus to voriconazole, posaconazole, itraconazole, and amphotericin B by the E-

173 The antifungal azoles, posaconazole, itraconazole, and ketoconazole, significan

174 Treatment with posaconazole led to complete resolution of the lesions.

175 Posaconazole levels in dHL-60 cells were 265-fold greate

176 Posaconazole-loaded cells were viable and maintained the

177 utropenic mouse model of IPA, treatment with posaconazole-loaded dHL-60 cells resulted in significant

178 These findings suggest that posaconazole-loading of leukocytes may hold promise for

179 We compared posaconazole M27-A2 and M38-A MICs to Etest and YeastOne

180 Fluconazole, voriconazole, and posaconazole MIC results for 10,807 isolates of Candida

181 n and micafungin MICs among Candida spp. and posaconazole MICs among C. albicans isolates and demonst

182 on coefficient was similar between reference posaconazole MICs and either disk (R, 0.810) or tablet (

183 Voriconazole and posaconazole MICs were 0.5-4 and 0.06-0.5 mg/L, respecti

184 olates of Candida spp. with a broad range of posaconazole MICs were tested using the CLSI M27-A2 meth

185 Posaconazole monotherapy or posaconazole combined with b

186 burden, compared with animals that received posaconazole monotherapy, in the cutaneous model of muco

187 c malignancies taking voriconazole (n = 20), posaconazole (n = 8), and itraconazole (n = 4), and a he

188 rmediate of an orally active antifungal drug posaconazole (Noxafil).

189 ive mold infections (IMIs) that occur during posaconazole or voriconazole prophylaxis are rare compli

190 le at a dose of 100 mg twice daily (low-dose posaconazole), or benznidazole at a dose of 150 mg twice

191 ns (MGCD290 in combination with fluconazole, posaconazole, or voriconazole) was performed by the chec

192 t of, standard antifungal therapies received posaconazole oral suspension (40 mg/mL) 800 mg daily in

193 g/kg of intravenous ABLC weekly or 200 mg of posaconazole orally three times per day as prophylaxis f

194 le (FL), itraconazole (I), voriconazole (V), posaconazole (P), flucytosine (FC), caspofungin (C), and

195 ing benznidazole monotherapy (p < 0.0001 vs. posaconazole/placebo).

196 Posaconazole plus MGCD290 demonstrated synergy against 1

197 oxaborale AN4169 cured 100% of mice, whereas posaconazole (POS), and NTLA-1 (a nitro-triazole) cured

198 MB), itraconazole (ITR), voriconazole (VOR), posaconazole (POS), and ravuconazole (RAV).

199 oles, fluconazole (FLC), itraconazole (ITC), posaconazole (POS), and voriconazole (VOR), was examined

200 oth dilution method with itraconazole (ITR), posaconazole (POS), ravuconazole (RAV), and voriconazole

201 (A Study of the Use of Oral Posaconazole [POS] in the Treatment of Asymptomatic Chro

202 e at a dose of 400 mg twice daily (high-dose posaconazole), posaconazole at a dose of 100 mg twice da

203 gh-risk episodes, prospectively managed with posaconazole primary prophylaxis and a uniform diagnosti

204 it demonstrates in a real-life setting that posaconazole prophylaxis confers an advantage in terms o

205 in the IFD-associated mortality rate, while posaconazole prophylaxis had a significant impact on ove

206 During the last years, the use of posaconazole prophylaxis in high-risk patients has signi

207 isseminated fusariosis that occurred despite posaconazole prophylaxis.

208 (CSF), micafungin (MCF), fluconazole (FLC), posaconazole (PSC), and voriconazole (VRC) for six rarer

209 itraconazole (ITRA), voriconazole (VRC), and posaconazole (PSZ) in 24 isolates of Candida glabrata wi

210 The investigational triazoles posaconazole, ravuconazole, and voriconazole had excelle

211 The investigational triazoles posaconazole, ravuconazole, and voriconazole were all hi

212 27-A2 document) MICs of three new triazoles (posaconazole, ravuconazole, and voriconazole) and the ec

213 ) and exhibited variable cross-resistance to posaconazole, ravuconazole, and voriconazole.

214 n B, flucytosine, fluconazole, itraconazole, posaconazole, ravuconazole, and voriconazole.

215 ility in three laboratories of itraconazole, posaconazole, ravuconazole, voriconazole, and amphoteric

216 to amphotericin B, flucytosine, fluconazole, posaconazole, ravuconazole, voriconazole, and caspofungi

217 the Etest method to detect voriconazole and posaconazole resistance among Aspergillus spp.

218 The performance of the Etest for posaconazole (SCH 56592) susceptibility testing of 314 i

219 Posaconazole showed antitrypanosomal activity in patient

220 . except C. glabrata (10.5% non-WT), whereas posaconazole showed decreased activity against C. albica

221 ppears to be a useful method for determining posaconazole susceptibilities of Candida species.

222 ple and reliable methods for determining the posaconazole susceptibilities of filamentous fungi.

223 ds a viable alternative to microdilution for posaconazole susceptibility testing.

224 ents may be useful as a surrogate marker for posaconazole susceptibility.

225 applied the voriconazole MIC breakpoints to posaconazole (susceptible, < or =1 microg/ml; susceptibl

226 The exceptions were the results for posaconazole tablets (R, 0.686; disk, 0.757; 84% categor

227 microg caspofungin and 1-microg voriconazole posaconazole tablets against all mold isolates, 8-microg

228 Combination posaconazole-tacrolimus therapy displays synergism in vi

229 ox, fluconazole, griseofulvin, itraconazole, posaconazole, terbinafine, and voriconazole.

230 ox, fluconazole, griseofulvin, itraconazole, posaconazole, terbinafine, and voriconazole.

231 The antifungal drug posaconazole that blocks sterol biosynthesis in the para

232 For posaconazole, the agreement was higher with M3 media (91

233 For posaconazole, the correlation was acceptable for Mucorom

234 ombination lipid polyene plus deferasirox or posaconazole therapy.

235 ent occurred within 6 weeks of initiation of posaconazole therapy; after 6 months, infection had reso

236 e absence of clinical breakpoints (CBPs) for posaconazole, these WT distributions and ECVs will be us

237 Agreement ranged from 92.3% with posaconazole to 98.0% with fluconazole.

238 tored in patients treated concomitantly with posaconazole to avoid toxicity from drug interaction.

239 but the infection continued to progress, so posaconazole treatment was begun and eventually led to t

240 n, 5-flucytosine, fluconazole, itraconazole, posaconazole, voriconazole, and amphotericin B by CLSI m

241 of isavuconazole, itraconazole, fluconazole, posaconazole, voriconazole, and the three echinocandins

242 gs tested were amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin,

243 amined the in vitro activity of caspofungin, posaconazole, voriconazole, ravuconazole, itraconazole,

244 Posaconazole was conjugated with the fluorophore boron-d

245 Among the triazoles, posaconazole was most active, inhibiting 95% of isolates

246 Cross-resistance between itraconazole and posaconazole was seen for 53.5% of the isolates, whereas

247 Posaconazole was the most frequently prescribed drug (26

248 Posaconazole was well tolerated and effective against IF

249 Treatment with posaconazole was well tolerated and induced a complete c

250 fluconazole, itraconazole, voriconazole, and posaconazole were compared to reference 48-h microdiluti

251 The MICs of amphotericin B and posaconazole were the lowest, and the MICs of triazoles

252 f 2 antifungals, amphotericin B products and posaconazole, with activity against Mucorales.

253 Benznidazole monotherapy is superior to posaconazole, with high RT-PCR conversion rates sustaine

254 eukemia, which was treated successfully with posaconazole without recurrence after a hematopoietic st